Table 3. Trends in prevalence of myeloproliferative neoplasm in Korea from 2003 to 2011, estimated with number of cases registered to Health Insurance Review and Assessment Service of Korea.
| MPN type | Sex | Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | |||
| MPN total | Total | Cases | 2,284 | 2,737 | 3,180 | 3,696 | 3,942 | 4,293 | 4,883 | 5,295 | 7,241 |
| CR | 6.04 | 7.10 | 7.99 | 9.10 | 9.62 | 9.99 | 11.03 | 11.67 | 12.56 | ||
| ASR | 5.48 | 6.28 | 6.89 | 7.70 | 7.89 | 7.94 | 8.46 | 8.65 | 9.02 | ||
| Men | Cases | 1,216 | 1,456 | 1,686 | 1,932 | 2,088 | 2,239 | 2,546 | 2,721 | 3,603 | |
| CR | 4.99 | 5.92 | 6.82 | 7.82 | 8.37 | 8.92 | 10.07 | 10.82 | 14.11 | ||
| ASR | 4.48 | 5.22 | 5.82 | 6.50 | 6.75 | 6.94 | 7.54 | 7.78 | 10.00 | ||
| Women | Cases | 1,068 | 1,281 | 1,494 | 1,764 | 1,854 | 2,054 | 2,337 | 2,574 | 3,638 | |
| CR | 4.42 | 5.27 | 6.11 | 7.20 | 7.50 | 8.25 | 9.33 | 10.21 | 14.34 | ||
| ASR | 4.05 | 4.73 | 5.34 | 6.21 | 6.25 | 6.70 | 7.36 | 7.84 | 10.84 | ||
| PV | Total | Cases | 1,188 | 1,364 | 1,516 | 1,673 | 1,749 | 1,824 | 2,006 | 2,114 | 2,304 |
| CR | 2.45 | 2.79 | 3.08 | 3.40 | 3.52 | 3.65 | 3.99 | 4.18 | 4.53 | ||
| ASR | 2.24 | 2.48 | 2.67 | 2.90 | 2.91 | 2.92 | 3.09 | 3.15 | 3.28 | ||
| Men | Cases | 688 | 813 | 907 | 1,033 | 1,096 | 1,138 | 1,243 | 1,285 | 1,386 | |
| CR | 2.82 | 3.31 | 3.67 | 4.18 | 4.39 | 4.53 | 4.92 | 5.16 | 5.43 | ||
| ASR | 2.55 | 2.92 | 3.16 | 3.53 | 3.60 | 3.61 | 3.78 | 3.80 | 3.91 | ||
| Women | Cases | 500 | 551 | 609 | 640 | 653 | 686 | 763 | 829 | 918 | |
| CR | 2.07 | 2.27 | 2.49 | 2.61 | 2.64 | 2.76 | 3.05 | 3.29 | 3.62 | ||
| ASR | 1.88 | 2.02 | 2.15 | 2.23 | 2.17 | 2.19 | 2.34 | 2.45 | 2.59 | ||
| MF | Total | Cases | 375 | 488 | 609 | 750 | 851 | 905 | 1,065 | 1,180 | 1,322 |
| CR | 0.77 | 1.00 | 1.24 | 1.52 | 1.71 | 1.81 | 2.12 | 2.33 | 2.60 | ||
| ASR | 0.69 | 0.88 | 1.06 | 1.27 | 1.38 | 1.41 | 1.59 | 1.70 | 1.83 | ||
| Men | Cases | 216 | 266 | 317 | 370 | 417 | 442 | 546 | 597 | 659 | |
| CR | 0.89 | 1.08 | 1.28 | 1.50 | 1.67 | 1.76 | 2.16 | 2.35 | 2.58 | ||
| ASR | 0.78 | 0.93 | 1.06 | 1.20 | 1.30 | 1.30 | 1.53 | 1.61 | 1.72 | ||
| Women | Cases | 159 | 222 | 292 | 380 | 434 | 463 | 519 | 583 | 663 | |
| CR | 0.66 | 0.91 | 1.19 | 1.55 | 1.76 | 1.86 | 2.07 | 2.31 | 2.61 | ||
| ASR | 0.60 | 0.82 | 1.04 | 1.33 | 1.45 | 1.51 | 1.62 | 1.77 | 1.93 | ||
| ET | Total | Cases | 721 | 885 | 1,055 | 1,273 | 1,342 | 1,564 | 1,812 | 2,001 | 3,615 |
| CR | 1.48 | 1.81 | 2.15 | 2.59 | 2.70 | 3.13 | 3.60 | 3.96 | 7.10 | ||
| ASR | 1.36 | 1.60 | 1.88 | 2.21 | 2.24 | 2.51 | 2.81 | 2.99 | 5.33 | ||
| Men | Cases | 312 | 377 | 462 | 529 | 575 | 659 | 757 | 839 | 1,558 | |
| CR | 1.28 | 1.53 | 1.87 | 2.14 | 2.31 | 2.63 | 2.99 | 3.31 | 6.10 | ||
| ASR | 1.15 | 1.37 | 1.60 | 1.77 | 1.85 | 2.03 | 2.23 | 2.37 | 4.37 | ||
| Women | Cases | 409 | 508 | 593 | 744 | 767 | 905 | 1,055 | 1,162 | 2,057 | |
| CR | 1.69 | 2.09 | 2.43 | 3.04 | 3.10 | 3.63 | 4.21 | 4.61 | 8.11 | ||
| ASR | 1.57 | 1.89 | 2.15 | 2.65 | 2.63 | 3.00 | 3.40 | 3.62 | 6.32 | ||
CR, crude rate; ASR, age-standardized rate; MPN, myeloproliferative neoplasm; PV, polycythemia vera; MF, primary myelofibrosis; ET, essential thrombocythemia.